ID   BON-1
AC   CVCL_3985
AS   CVCL_B390
SY   Bon-1; BON1; BON
DR   BTO; BTO:0003856
DR   cancercelllines; CVCL_3985
DR   Cosmic; 721017
DR   Cosmic; 1620107
DR   Cosmic; 1879411
DR   Cosmic; 2433550
DR   Cosmic; 2530675
DR   Wikidata; Q54797946
RX   CelloPub=CLPUB00598;
RX   PubMed=1712329;
RX   PubMed=7978888;
RX   PubMed=8108375;
RX   PubMed=19295186;
RX   PubMed=22538498;
RX   PubMed=22929519;
RX   PubMed=25612765;
RX   PubMed=26087898;
RX   PubMed=29330294;
RX   PubMed=29444910;
RX   PubMed=29895527;
RX   PubMed=32884006;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=BON
CC   Doubling time: 1.5 +- 0.4 days (PubMed=29330294); 46 +- 0.72 hours (PubMed=32884006).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Heterozygous (PubMed=29444910).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1960Tyr (c.5879G>A); ClinVar=VCV000038003; Zygosity=Heterozygous (PubMed=29444910).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910).
CC   Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Arg1329His (c.3986G>A); ClinVar=VCV000041738; Zygosity=Unspecified (PubMed=25612765).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): PubMed=29444910
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 11,12
ST   D16S539: 10,11
ST   D21S11: 28,33.2
ST   D5S818: 9,12
ST   D7S820: 9
ST   TH01: 8
ST   TPOX: 9
ST   vWA: 18,19
DI   NCIt; C4446; Pancreatic serotonin-producing neuroendocrine tumor
DI   ORDO; Orphanet_506090; Serotonin-producing neuroendocrine tumor of pancreas
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   28Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 17
//
RX   CelloPub=CLPUB00598;
RA   Behrang Y.;
RT   "Establishment and characterization of a new human, highly
RT   differentiated and functionally active tumor model of a pancreatic
RT   neuroendocrine tumor.";
RL   Thesis MD (2020), University of Hamburg, Germany.
//
RX   PubMed=1712329; DOI=10.5555/uri:pii:0016508591900045;
RA   Evers B.M., Townsend C.M. Jr., Upp J.R. Jr., Allen E., Hurlbut S.C.,
RA   Kim S.W., Rajaraman S., Singh P., Reubi J.-C., Thompson J.C.;
RT   "Establishment and characterization of a human carcinoid in nude mice
RT   and effect of various agents on tumor growth.";
RL   Gastroenterology 101:303-311(1991).
//
RX   PubMed=7978888; DOI=10.1111/j.1749-6632.1994.tb17289.x;
RA   Evers B.M., Ishizuka J., Townsend C.M. Jr., Thompson J.C.;
RT   "The human carcinoid cell line, BON. A model system for the study of
RT   carcinoid tumors.";
RL   Ann. N. Y. Acad. Sci. 733:393-406(1994).
//
RX   PubMed=8108375; DOI=10.1097/00006676-199401000-00013;
RA   Parekh D., Ishizuka J., Townsend C.M. Jr., Haber B., Beauchamp R.D.,
RA   Karp G., Kim S.W., Rajaraman S., Greeley G. Jr., Thompson J.C.;
RT   "Characterization of a human pancreatic carcinoid in vitro:
RT   morphology, amine and peptide storage, and secretion.";
RL   Pancreas 9:83-90(1994).
//
RX   PubMed=19295186; DOI=10.1159/000209330;
RA   Siddique Z.-L., Drozdov I., Floch J., Gustafsson B.I., Stunes K.,
RA   Pfragner R., Kidd M., Modlin I.M.;
RT   "KRJ-I and BON cell lines: defining an appropriate enterochromaffin
RT   cell neuroendocrine tumor model.";
RL   Neuroendocrinology 89:458-470(2009).
//
RX   PubMed=22538498; DOI=10.1159/000338793;
RA   Grozinsky-Glasberg S., Shimon I., Rubinfeld H.;
RT   "The role of cell lines in the study of neuroendocrine tumors.";
RL   Neuroendocrinology 96:173-187(2012).
//
RX   PubMed=22929519; DOI=10.3791/4218;
RA   Wong C., Vosburgh E., Levine A.J., Cong L., Xu E.Y.;
RT   "Human neuroendocrine tumor cell lines as a three-dimensional model
RT   for the study of human neuroendocrine tumor therapy.";
RL   J. Vis. Exp. 66:e4218.1-e4218.7(2012).
//
RX   PubMed=25612765; DOI=10.1530/JME-14-0304;
RA   Vandamme T., Peeters M., Dogan F., Pauwels P., Van Assche E.,
RA   Beyens M., Mortier G., Vandeweyer G., de Herder W., Van Camp G.,
RA   Hofland L.J., Op de Beeck K.;
RT   "Whole-exome characterization of pancreatic neuroendocrine tumor cell
RT   lines BON-1 and QGP-1.";
RL   J. Mol. Endocrinol. 54:137-147(2015).
//
RX   PubMed=26087898; DOI=10.1016/j.cancergen.2015.04.002;
RA   Boora G.K., Kanwar R., Kulkarni A.A., Pleticha J., Ames M.,
RA   Schroth G., Beutler A.S., Banck M.S.;
RT   "Exome-level comparison of primary well-differentiated neuroendocrine
RT   tumors and their cell lines.";
RL   Cancer Genet. 208:374-381(2015).
//
RX   PubMed=29330294; DOI=10.1158/1541-7786.MCR-17-0163;
RA   Benten D., Behrang Y., Unrau L., Weissmann V., Wolters-Eisfeld G.,
RA   Burdak-Rothkamm S., Stahl F.R., Anlauf M., Grabowski P., Mobs M.,
RA   Dieckhoff J., Sipos B., Fahl M., Eggers C., Perez D., Bockhorn M.,
RA   Izbicki J.R., Lohse A.W., Schrader J.;
RT   "Establishment of the first well-differentiated human pancreatic
RT   neuroendocrine tumor model.";
RL   Mol. Cancer Res. 16:496-507(2018).
//
RX   PubMed=29444910; DOI=10.1530/ERC-17-0445;
RA   Hofving T., Arvidsson Y., Almobarak B., Inge L., Pfragner R.,
RA   Persson M., Stenman G., Kristiansson E., Johanson V., Nilsson O.;
RT   "The neuroendocrine phenotype, genomic profile and therapeutic
RT   sensitivity of GEPNET cell lines.";
RL   Endocr. Relat. Cancer 25:367-380(2018).
//
RX   PubMed=29895527; DOI=10.1530/ERC-18-0159;
RA   Aristizabal Prada E.T., Spottl G., Maurer J., Lauseker M.,
RA   Koziolek E.J., Schrader J., Grossman A., Pacak K., Beuschlein F.,
RA   Auernhammer C.J., Nolting S.;
RT   "The role of GSK3 and its reversal with GSK3 antagonism in everolimus
RT   resistance.";
RL   Endocr. Relat. Cancer 25:893-908(2018).
//
RX   PubMed=32884006; DOI=10.1038/s41598-020-71516-7;
RA   Monazzam A., Li S.-C., Wargelius H., Razmara M., Bajic D., Mi J.,
RA   Bergquist J., Crona J., Skogseid B.;
RT   "Generation and characterization of CRISPR/Cas9-mediated MEN1 knockout
RT   BON1 cells: a human pancreatic neuroendocrine cell line.";
RL   Sci. Rep. 10:14572-14572(2020).
//